Tissue-specific changes in mRNA expression of Abc and Slc transporters in murine pulmonary tuberculosis Transporters

Xenobiotica

Volumn 39, Issue 10, 2009, Pages 738-748

  Lee, S H ^a   Oh, T ^b   Jeon, B Y ^b   Kwak, E Y ^a   Shim, W S ^a   Cho, S N ^b   Kim, D D ^a   Chung, S J ^a   Shim, C K ^a  

^a Seoul National University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Mouse infection; Real time polymerase chain reaction (PCR); Transporter; Tuberculosis

Indexed keywords

ABC TRANSPORTER; CARRIER PROTEINS AND BINDING PROTEINS; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; SLC TRANSPORTER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG DISPOSITION; FEMALE; HOMEOSTASIS; LUNG TUBERCULOSIS; MEMBRANE TRANSPORT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE;

ANIMALS; ANION TRANSPORT PROTEINS; ATP-BINDING CASSETTE TRANSPORTERS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; RNA, MESSENGER; TUBERCULOSIS, PULMONARY;

ANIMALIA; MURINAE; MUS; MYCOBACTERIUM TUBERCULOSIS;

EID: 70350643911     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250903089829     Document Type: Article

References (58)

1. Abba K, Sudarsanam T, Grobler L, Volmink J. (2008). Nutritional supplements for people being treated for active tuberculosis. Cochrane Database Syst Rev 4:CD006086.
2. Alrefai WA, Gill RK. (2007). Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 24(10):1803-1823
3. Alvarez AI, Perez M, Prieto JG, Molina AJ, Real R, Merino G. (2008). Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci 97(9):3483-3493
4. Athanassakis I, Mouratidou M, Sakka P, Evangeliou A, Spilioti M, Vassiliadis S. (2001). L-carnitine modifies the humoral immune response in mice after in vitro or in vivo treatment. Int Immunopharmacol 1(9-10):1813-1822
5. Ban N, Matsumura Y, Sakai H, Takanezawa Y, Sasaki M, Arai H, Inagaki N. (2007). ABCA3 as a lipid transporter in pulmonary surfactant biogenesis. J Biol Chem 282(13):9628-9634
6. Basaraba RJ. (2008). Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis 88(1):S35-47.
7. Berg S, Sappington P, Guzik L, Delude R, Fink M. (2003). Proinflammatory cytokines increase the rate of glycolysis and adenosine-5́-triphosphate turnover in cultured rat enterocytes. Crit Care Med 31(4):1203-1212
8. Bottasso O, Bay M, Besedovsky H, del Rey A. (2007). The immuno-endocrine component in the pathogenesis of tuberculosis. Scand J Immunol 66(2-3):166-175
9. Chackerian A, Alt J, Perera T, Dascher C, Behar S. (2002). Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 70(8):4501-4509
10. Chen M, Divangahi M, Gan H, Shin D, Hong S, Lee D, Serhan C, Behar S, Remold H. (2008). Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med 205(12):2791-2801
11. Cheng Q, Aleksunes LM, Manautou JE, Cherrington NJ, Scheffer GL, Yamasaki H, Slitt AL. (2008). Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol Pharm 5(1):77-91.
12. Chimote G, Banerjee R. (2005). Lung surfactant dysfunction in tuberculosis: effect of mycobacterial tubercular lipids on dipalmitoylphosphatidylcholine surface activity. Colloids Surf B Biointerfaces 45(3-4):215-223
13. Chimote G, Banerjee R. (2008). Effect of mycobacterial lipids on surface properties of Curosurf: implications for lung surfactant dysfunction in tuberculosis. Respir Physiol Neurobiol 162(1):73-79
14. Deeley RG, Westlake C, Cole SP. (2006). Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86(3):849-899
15. Dresser MJ, Leabman MK, Giacomini KM. (2001). Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 90(4):397-421.
16. Fitzgerald ML, Xavier R, Haley KJ, Welti R, Goss JL, Brown CE, Zhuang DZ, Bell SA, Lu N, McKee M, Seed B, Freeman MW. (2007). ABCA3 inactivation in mice causes respiratory failure, loss of pulmonary surfactant, and depletion of lung phosphatidylglycerol. J Lipid Res 48(3):621-632
17. Gabler NK, Radcliffe JS, Spencer JD, Webel DM, Spurlock ME. (2009). Feeding long-chain n-3 polyunsaturated fatty acids during gestation increases intestinal glucose absorption potentially via the acute activation of AMPK. J Nutr Biochem 20(1):17-25.
18. Garay SM. (1996). Pulmonary tuberculosis. In: Rom WN, Garay SM, editors. Tuberculosis. New York, NY: Little Brown. p. 373-441.
19. Hagenbuch B, Gui C. (2008). Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38(7-8):778-801.
20. Hernández-Pando R, Orozcoe H, Sampieri A, Pavón L, Velasquillo C, Larriva-Sahd J, Alcocer J, Madrid M. (1996). Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 89(1):26-33.
21. Hofmann AF, Hagey LR. (2008). Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci 65(16):2461-2483
22. Jirillo E, Altamura M, Marcuccio C, Tortorella C, De Simone C, Antonaci S. (1993). Immunological responses in patients with tuberculosis and in vivo effects of acetyl-L-carnitine oral administration. Mediators Inflamm 2(7):S17-20.
23. Jozefowski S, Sobota A, Kwiatkowska K. (2008). How Mycobacterium tuberculosis subverts host immune responses. Bioessays 30(10):943-954
24. Kashino S, Pollock N, Napolitano D, Rodrigues VJ, Campos-Neto A. (2008). Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin Exp Immunol 153(1):56-62.
25. Kaufmann S, Cole S, Mizrahi V, Rubin E, Nathan C. (2005). Mycobacterium tuberculosis and the host response. J Exp Med 201(11):1693-1697
26. Kaufmann SH. (2003). Immune response to tuberculosis: experimental animal models. Tuberculosis 83(1-3):107-111
27. Koepsell H, Lips K, Volk C. (2007). Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24(7):1227-1251
28. Lammert F, Wang D, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B, Carey M. (2004). Spontaneous cholecysto-and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology 39(1):117-128
29. Lenaerts AJ, Degroote MA, Orme IM. (2008). Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol 16(2):48-54.
30. Lin ZP, Zhu YL, Johnson DR, Rice KP, Nottoli T, Hains BC, McGrath J, Waxman SG, Sartorelli AC. (2008). Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response. Mol Pharmacol 73(1):243-251
31. Loffler M, Morote-Garcia JC, Eltzschig SA, Coe IR, Eltzschig HK. (2007). Physiological roles of vascular nucleoside transporters. Arterioscler Thromb Vasc Biol 27(5):1004-1013
32. Martens GW, Arikan MC, Lee J, Ren F, Vallerskog T, Kornfeld H. (2008). Hypercholesterolemia impairs immunity to tuberculosis. Infect Immun 76(8):3464-3472
33. Mogues T, Goodrich M, Ryan L, LaCourse R, North R. (2001). The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 193(3):271-280
34. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ. (2008). Regulation of drugmetabolizing enzymes and transporters in infection, inflammation, and cancer: Drug Metab Dispos. 36(2):205-216
35. Munoz-Elias EJ, Upton AM, Cherian J, McKinney JD. (2006). Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence. Mol Microbiol 60(5):1109-1122
36. Nathan C, Gold B, Lin G, Stegman M, de Carvalho L, Vandal O, Venugopal A, Bryk R. (2008). A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis. Tuberculosis (Edinb) 88 (Suppl. 1):S25-33.
37. North RJ, Jung YJ. (2004). Immunity to tuberculosis. Annu Rev Immunol 22:599-623.
38. Nunn A, Phillips P, Gillespie S. (2008). Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb) 88 (Suppl. 1):S85-92.
39. Oude Elferink RP, Paulusma CC. (2007). Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch 453(5):601-610
40. Palmieri O, Latiano A, Valvano R, D'Incà R, Vecchi M, Sturniolo GC, Saibeni S, Peyvandi F, Bossa F, Zagaria C, Andriulli A, Devoto M, Annese V. (2006). Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 23(4):497-506.
41. Pastor-Anglada M, Cano-Soldado P, Errasti-Murugarren E, Casado FJ. (2008). SLC28 genes and concentrative nucleoside transporter (CNT) proteins. Xenobiotica 38(7-8):972-994
42. Peres C, de Paula L, Medeiros A, Sorgi C, Soares E, Carlos D, Peters-Golden M, Silva C, Faccioli L. (2007). Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis. Microbes Infect 9(4):483-489
43. Pérez-Guzmán C, Vargas M, Quiñonez F, Bazavilvazo N, Aguilar A. (2005). A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis. Chest 127(2):643-651
44. Pinheiro VG, Ramos LM, Monteiro HS, Barroso EC, Bushen OY, Facanha MC, Peloquin CA, Guerrant RL, Lima AA. (2006). Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis. Braz J Infect Dis 10(6):374-379
45. Rangel Moreno J, Estrada García I, De La Luz García Hernández M, Aguilar Leon D, Marquez R, Hernández Pando R. (2002). The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology 106(2):257-266
46. Rius M, Hummel-Eisenbeiss J, Keppler D. (2008). ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4). J Pharmacol Exp Ther 324(1):86-94.
47. Rizwan AN, Burckhardt G. (2007). Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 24(3):450-470
48. Rozen S, Skaletsky HJ. 2000. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, editors. Bioinformatics methods and protocols: methods in molecular biology. Totowa, NJ: Humana. p. 365-386
49. Russel FG, Koenderink JB, Masereeuw R. (2008). Multidrug resistance protein 4 (MRP4/ABCC4): a versatile effl ux transporter for drugs and signalling molecules. Trends Pharmacol Sci 29(4):200-207
50. Sacks L, Behrman R. (2008). Developing new drugs for the treatment of drug-resistant tuberculosis: a regulatory perspective. Tuberculosis (Edinb) 88 (Suppl. 1):S93-100.
51. Shekhawat PS, Srinivas SR, Matern D, Bennett MJ, Boriack R, George V, Xu H, Prasad PD, Roon P, Ganapathy V. (2007). Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(-/-)) mice. Mol Genet Metab 92(4):315-324
52. Shitara Y, Horie T, Sugiyama Y. (2006). Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27(5):425-446
53. Towler MC, Hardie DG. (2007). AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100(3):328-341
54. Tsuji A. (2006). Impact of transporter-mediated drug absorption, distribution, elimination and drug interactions in antimicrobial chemotherapy. J Infect Chemother 12(5):241-250
55. Van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J. (2007). Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 81(3):414-419
56. Voshol PJ, Havinga R, Wolters H, Ottenhoff R, Princen HM, Oude Elferink RP, Groen AK, Kuipers F. (1998). Reduced plasma cholesterol and increased fecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice. Gastroenterology 114(5):1024-1034
57. Weber SS, Ragaz C, Hilbi H. (2009). Pathogen trafficking pathways and host phosphoinositide metabolism. Mol Microbiol 4:4.
58. Zaher H, zu Schwabedissen HE, Tirona RG, Cox ML, Obert LA, Agrawal N, Palandra J, Stock JL, Kim RB, Ware JA. (2008). Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol 74(2):320-329